News & Updates

Survival benefit with STRIDE for HCC sustained at 5 years

10 Jan 2025 by

The updated exploratory analysis of the phase III HIMALAYA trial demonstrates a significant overall survival (OS) benefit at 5 years with the STRIDE* regimen comprising tremelimumab and durvalumab for patients with unresectable hepatocellular carcinoma (HCC).

Survival benefit with STRIDE for HCC sustained at 5 years

10 Jan 2025

Maternal NAFLD ups risk of adverse pregnancy outcomes

09 Jan 2025

Pregnant women with nonalcoholic fatty liver disease (NAFLD) face a greater risk of adverse pregnancy events, suggests a genome-wide association study.

Maternal NAFLD ups risk of adverse pregnancy outcomes

09 Jan 2025

Oral bacteria a risk factor for HNSCC development

09 Jan 2025 by

A prospective nested case-control study yields compelling evidence that oral bacteria are a risk factor for the development of head and neck squamous cell carcinoma (HNSCC), which comprises cancers of the oral cavity, pharynx, and larynx.

Oral bacteria a risk factor for HNSCC development

09 Jan 2025

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

07 Jan 2025 by

The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

07 Jan 2025

Original New Drug Application Approvals by US FDA (16-31 December 2024)

07 Jan 2025

New drug applications approved by US FDA as of 16-31 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 December 2024)

07 Jan 2025

Vedolizumab after resection helps prevent CD recurrence

05 Jan 2025

For patients with Crohn’s disease (CD) who are scheduled to undergo ileocolonic resection, initiating vedolizumab treatment promptly after the procedure has the potential to prevent recurrence, according to the results of the REPREVIO study.

Vedolizumab after resection helps prevent CD recurrence

05 Jan 2025

Unleashing Innovation and Updates in Clinical Practice.

27 Dec 2024

On October 25, 2024, gastroenterologists and hepatologists gathered at the Globe Auditorium, BGC braving the raging typhoon to listen to top experts talk about updates in clinical practice in managing liver disease. This was the second installment of a 2-day lecture series sponsored by Opella Healthcare Philippines.

Unleashing Innovation and Updates in Clinical Practice.

27 Dec 2024

Golden Liver Health Forum: Multidisciplinary Approaches to Cardiometabolic and Liver Disease Management

27 Dec 2024

The Golden Liver Health Forum, convened on October 24, 2024, at the Globe Auditorium in BGC, presented evolving multi-disciplinary strategies in managing Metabolic Associated Fatty Liver Disease (MAFLD). Through insightful discussions from top experts in endocrinology, cardiology, and hepatology—Bien Matawaran, MD, Louella Santos, MD, and Stephen Wong, MD, chaired by Prof Jose D. Sollano Jr., MD, the forum provided clinicians with valuable, patient-centered strategies that enhance risk assessment and management for these intertwined health concerns.

Golden Liver Health Forum: Multidisciplinary Approaches to Cardiometabolic and Liver Disease Management

27 Dec 2024

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024 by

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024

New UC guideline endorses early use of advanced therapies

27 Dec 2024 by

The American Gastroenterological Association (AGA), in an update to its living practice guideline, recommends the early use of advanced therapies for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in adult outpatients.

New UC guideline endorses early use of advanced therapies

27 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Survival benefit with STRIDE for HCC sustained at 5 years

Survival benefit with STRIDE for HCC sustained at 5 years

Maternal NAFLD ups risk of adverse pregnancy outcomes

Maternal NAFLD ups risk of adverse pregnancy outcomes

Oral bacteria a risk factor for HNSCC development

Oral bacteria a risk factor for HNSCC development

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

Original New Drug Application Approvals by US FDA (16-31 December 2024)

Original New Drug Application Approvals by US FDA (16-31 December 2024)

Vedolizumab after resection helps prevent CD recurrence

Vedolizumab after resection helps prevent CD recurrence

Unleashing Innovation and Updates in Clinical Practice.

Unleashing Innovation and Updates in Clinical Practice.

Golden Liver Health Forum: Multidisciplinary Approaches to Cardiometabolic and Liver Disease Management

Golden Liver Health Forum: Multidisciplinary Approaches to Cardiometabolic and Liver Disease Management

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

New UC guideline endorses early use of advanced therapies

New UC guideline endorses early use of advanced therapies